These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 28571695)

  • 1. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
    Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
    Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process.
    George M; Farooq M; Dang T; Cortes B; Liu J; Maranga L
    Biotechnol Bioeng; 2010 Aug; 106(6):906-17. PubMed ID: 20589670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells.
    Hussain AI; Cordeiro M; Sevilla E; Liu J
    Vaccine; 2010 May; 28(22):3848-55. PubMed ID: 20307595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avian Cell Line DuckCelt
    Chupin C; Pizzorno A; Traversier A; Brun P; Ogonczyk-Makowska D; Padey B; Milesi C; Dulière V; Laurent E; Julien T; Galloux M; Lina B; Eléouët JF; Moreau K; Hamelin ME; Terrier O; Boivin G; Dubois J; Rosa-Calatrava M
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells.
    Lohr V; Genzel Y; Jordan I; Katinger D; Mahr S; Sandig V; Reichl U
    BMC Biotechnol; 2012 Oct; 12():79. PubMed ID: 23110398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production and antigenic properties of influenza virus from suspension MDCK-siat7e cells in a bench-scale bioreactor.
    Chu C; Lugovtsev V; Lewis A; Betenbaugh M; Shiloach J
    Vaccine; 2010 Oct; 28(44):7193-201. PubMed ID: 20800699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental studies from shake flasks to 3 L stirred tank bioreactor of nutrients and oxygen supply conditions to improve the growth of the avian cell line DuckCelt®-T17.
    Tingaud V; Bordes C; Al Mouazen E; Cogné C; Bolzinger MA; Lawton P
    J Biol Eng; 2023 Apr; 17(1):31. PubMed ID: 37095522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
    Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
    BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Vero-cell-adapted vaccine donor strain of influenza A virus generated by serial passages.
    Hu W; Zhang H; Han Q; Li L; Chen Y; Xia N; Chen Z; Shu Y; Xu K; Sun B
    Vaccine; 2015 Jan; 33(2):374-81. PubMed ID: 25448099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Y161F Hemagglutinin Substitution Increases Thermostability and Improves Yields of 2009 H1N1 Influenza A Virus in Cells.
    Wen F; Li L; Zhao N; Chiang MJ; Xie H; Cooley J; Webby R; Wang PG; Wan XF
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29118117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
    Gränicher G; Coronel J; Pralow A; Marichal-Gallardo P; Wolff M; Rapp E; Karlas A; Sandig V; Genzel Y; Reichl U
    Vaccine; 2019 Nov; 37(47):7019-7028. PubMed ID: 31005427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a High-Growth Influenza Vaccine Strain in MDCK Cells for Vaccine Preparedness.
    Kim EH; Kwon HI; Park SJ; Kim YI; Si YJ; Lee IW; Kim SM; Kim SI; Ahn DH; Choi YK
    J Microbiol Biotechnol; 2018 Jun; 28(6):997-1006. PubMed ID: 29642288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect".
    Tapia F; Wohlfarth D; Sandig V; Jordan I; Genzel Y; Reichl U
    PLoS One; 2019; 14(11):e0224317. PubMed ID: 31689309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture.
    Genzel Y; Fischer M; Reichl U
    Vaccine; 2006 Apr; 24(16):3261-72. PubMed ID: 16472544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and Genetic Characterization of Avian Influenza H5N2 Viruses with Intra- and Inter-Duck Variations in Taiwan.
    Li YT; Ko HY; Lee CC; Lai CY; Kao CL; Yang C; Wang WB; King CC
    PLoS One; 2015; 10(8):e0133910. PubMed ID: 26263554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
    Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
    Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
    Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing.
    Donis RO; ; Davis CT; Foust A; Hossain MJ; Johnson A; Klimov A; Loughlin R; Xu X; Tsai T; Blayer S; Trusheim H; Colegate T; Fox J; Taylor B; Hussain A; Barr I; Baas C; Louwerens J; Geuns E; Lee MS; Venhuizen O; Neumeier E; Ziegler T
    Vaccine; 2014 Nov; 32(48):6583-90. PubMed ID: 24975811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
    Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
    Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in MDCK cells.
    Frensing T; Kupke SY; Bachmann M; Fritzsche S; Gallo-Ramirez LE; Reichl U
    Appl Microbiol Biotechnol; 2016 Aug; 100(16):7181-92. PubMed ID: 27129532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.